GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.
Video Player is loading.
EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care
EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring
EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
Now Viewing
EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
EP: 9.Treatment Strategies in ctDNA-Positive CRC
EP: 10.GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
EP: 11.CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis
Recent Videos
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
Key Takeaways and Future in Advanced Gastric Cancer Treatment
Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
Related Content
